Moffitt requests support (10.8 calendar months, FTE, $225,849) for an experienced leadership team that includes: ? William S. Dalton, PhD, MD, Center Director ? W. Jack Pledger, PhD, Deputy Center Director and Associate Center Director for Basic Sciences ? Thomas Sellers, PhD, Associate Center Director for Cancer Prevention and Control ? Daniel Sullivan, MD, Associate Center Director for Clinical Investigations ? James Mule, PhD, Associate Center Director for Translational Research In addition, the Senior Leadership description and request for the Vice President for Research, Michael Benedict, PhD, is included in the Administration section. Responsibility and final authority for all scientific, clinical and operational decisions reside with the Center Director, Dr. William Dalton, who is the Chief Executive Officer of the organization. Reporting directly to the Center Director are four Executive Vice Presidents/Associate Center Directors (ACDs), who are responsible for coordinating research activities of the Center along with a Vice President for Research. The Center Director and senior leaders interact frequently including weekly meetings. The Associate Center Directors and Vice President of Research meet weekly as the Research Executive Committee to discuss research related issues. Clearly defined roles for both leadership and the advisory bodies contribute to Moffitt's ability to move quickly and strategically to meet its goals. Over the last five years, two changes relevant to the CCSG senior leadership occurred: ? In 2007, Michael Benedict, PharmD was recruited as Vice President of Clinical Investigations. With the retirement of Anne Goff in 2009, Dr. Benedict was appointed the sole Vice President of Research. ? James Mule, PhD's senior leadership role as Executive Vice President has evolved and he now serves as EVP and Associate Center Director of Translational Research. He replaces Timothy Yeatman, MD, whose leadership role shifted to another area of the Cancer Center.

Public Health Relevance

The Senior Leaders oversee the Center's overall operations of research including strategic planning, recruitment, CCSG oversight, translational and collaborative efforts, the interface between research and clinical activities, and the implementation of policy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82
Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61
Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7
Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6
Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83
Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1
Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50
Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888

Showing the most recent 10 out of 108 publications